IBOGAINE RESEARCH & OPIOID ADDICTION

 Full article: Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes (tandfonline.com) (Overview presentation: Brown_GITA_Vancouver_Oct2012_iboga_comm_rev.pdf (maps.org))   

Thomas Kingsley Brown & Kenneth Alper

"Consistent with its apparent effect in opioid detoxification in humans, ibogaine administered intraperitoneally or intracerebrally to animals reduces naloxone- or naltrexone-precipitated opioid withdrawal signs, in rats, mice, and primates. Single dosages of ibogaine administered to rodents diminish self-administration of multiple abused substances including morphine , heron, cocaine, amphetamine, and alcohol, with normal responding for water. "

 Full article: Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study (tandfonline.com) (Overview Presentation: Microsoft PowerPoint - Cutting Edge Noller.ppt [Compatibility Mode] (maps.org

 "Conclusion: A single ibogaine treatment reduced opioid withdrawal symptoms and achieved opioid cessation or sustained reduced use in dependent individuals as measured over 12 months. Ibogaine’s legal availability in New Zealand may offer improved outcomes where legislation supports treatment providers to work closely with other health professionals."

  Geoffrey E. Noller, Chris M. Frampton & Berra Yazar-Klosinski

 (Both of the above studies are directly from the MAPS website, Ibogaine - Multidisciplinary Association for Psychedelic Studies - MAPS) 

Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning - PMC (nih.gov)  Alan K. Davis, Joseph Barsuglia, Austin-Marley Windham Herman, Marta Lynch and Martin Polanco 

 "Results: Most participants (72%) had used opioids for at least 4 years and 69% reported daily use. Most (80%) indicated that ibogaine eliminated or drastically reduced withdrawal symptoms. Fifty percent reported that ibogaine reduced opioid craving, some (25%) reporting a reduction in craving lasting at least 3 months. Thirty percent of participants reported never using opioids again following ibogaine treatment. And over one half (54%) of these abstainers had been abstinent for at least 1 year, with 31% abstinent for at least 2 years. At the time of survey, 41% of all participants reported sustained abstinence (>6 months). Although 70% of the total sample reported a relapse following treatment, 48% reported decreased use from pretreatment levels and an additional 11% eventually achieved abstinence. Treatment responders had the lowest rates of depressive and anxious symptoms, the highest levels of subjective well-being and rated their ibogaine treatment as more spiritually meaningful compared with treatment non-responders. "

"Conclusion:  The results suggest that ibogaine is associated with reductions in opioid use, including complete abstinence, and has long-term positive psychological outcomes. Future research should investigate the efficacy of ibogaine treatment using rigorous longitudinal and controlled designs. "

Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes - PMC (nih.gov)   

Deborah C. Mash, Linda Duque, Bryan Page, and Kathleen Allen-Ferdinand

" High rates of depressive disorders are reported among people seeking treatment for substance abuse disorders (for review, Nunes and Levin, 2004). The rapid improvement in depressive mood following ibogaine administration may offer an additional benefit for opioid detoxification when compared to an opioid substitution taper or lofexidine as withdrawal agents... Ibogaine may help opioid dependent patients to transition to sobriety and to establish a substance-free recovery because the oneirophrenic effects have therapeutic benefit as an adjuvant to psychotherapy (Alper et al., 1999; Davis et al., 2017; Mash, 2018). The elicitation narratives described in this report suggest that ibogaine may promote harm reduction following detoxification from opioids. "

The Reason Foundation: Ibogaine Treatment for Opioid Use Disorder   by Madison Carlino  Project Director: Geoffrey Lawrence 

From the Executive Summary:  "A consistent theme emerges from the research conducted to date into ibogaine as a  prospective treatment for opioid use disorder (OUD): Ibogaine and ibogaine analogues are  the only known treatments that consistently and immediately reduce both physical  withdrawal symptoms from opioid addiction and psychological dependence without the  need for ongoing medication. However, there are no large-scale studies of ibogaine and  more research is needed to understand if it could satisfy patients’ medical needs... Based on existing research, ibogaine therapy shows potential to be an effective alternative  treatment method for OUD. Its ability to reduce and eliminate opioid withdrawal and  craving symptoms plays a key role in the reduction and abstinence of illicit opioid use.  Hence, ibogaine can help users achieve lasting anti-addictive effects at fewer doses,  whereas traditional MATs just abate dependence. Policymakers should consider ibogaine as  a potential alternative treatment for OUD. "

Podcasts & Video Content

Bryan Hubbard (former Chairman of the Kentucky Opioid Abatement Commission and currently the REID Foundation's Executive Director of the American Ibogaine Initiative) and former Governor Rick Perry on The Joe Rogan Experience discussing Ibogaine:  Joe Rogan Experience #2251 - Rick Perry & W. Bryan Hubbard 

New York's First Ibogaine Town Hall featuring longtime activist Dana Beal, Bryan Hubbard, Juliana Mulligan of Inner Visions Ibogaine, Noah Daily of Lucid News, and more:  Ibogaine Town Hall 12/14 - YouTube 

Please click here to see relevant bills at the NY State level